Awaiting development: Guidance and quality standards

Showing 241 to 250 of 285

Guidance and quality standards awaiting development
Title	Type
Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191]	Technology appraisal guidance
Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6628]	Technology appraisal guidance
Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915]	Technology appraisal guidance
Tildrakizumab for treating active psoriatic arthritis [TSID12218]	Technology appraisal guidance
Timrepigene emparvovec for treating choroideremia [ID3916]	Technology appraisal guidance
Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]	Technology appraisal guidance
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]	Technology appraisal guidance
Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064]	Technology appraisal guidance
Tiratricol for treating Allan–Herndon–Dudley syndrome [ID6217]	Technology appraisal guidance
Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]	Technology appraisal guidance